Sandoz to Acquire Aspen’s Japanese Operations and Associated Assets for ~$440M

Shots:

• Aspen to receive $330.68M up front along with up to $110.22M deferred consideration upon fulfillment of certain conditions, making a total deal value ~$440.9M. The transaction is anticipated to be closed in H1’20
• The acquisition will complement Sandoz’s hospital generic and biosimilar portfolio, further expand its access to the hospital channel in Japan and allow Sandoz to bolster its position in the world’s third-largest generics market
• Additionally, the companies sign a manufacturing and supply agreement (with an additional two-year extension option) for 5yrs. Aspen’s portfolio in Japan consists of ~20 products, off-patent medicines focusing on anesthetics (including Xylocaine), specialty brands (including Imuran) and local brands

Click here to­ read full press release/ article | Ref: Novartis  | Image: Aspen Group Site